Loading...
•
Dec 31, 2023
Ultragenyx Q4 2023 Earnings Report
Ultragenyx reported Q4 2023 financial results, demonstrating revenue growth and pipeline advancements.
Key Takeaways
Ultragenyx reported a 23% increase in total revenue for Q4 2023, reaching $127 million. The company saw growth in Crysvita and Dojolvi sales. They are focused on advancing their Phase 3 programs and executing commercial product launches.
Total revenue for Q4 2023 was $127 million, a 23% increase compared to Q4 2022.
Crysvita revenue for Q4 2023 was $94 million, a 17% increase compared to Q4 2022, including significant growth in Latin America and Turkey.
Dojolvi revenue for Q4 2023 was $23 million, a 42% increase compared to Q4 2022.
Net loss for Q4 2023 was $123 million, or $1.52 per share, compared to a net loss of $152 million, or $2.16 per share, for Q4 2022.
Revenue by Segment
Forward Guidance
Ultragenyx reaffirms its financial guidance for the full year 2024.
Positive Outlook
- Total revenue is expected to be in the range of $500 million to $530 million.
- Crysvita revenue is expected to be in the range of $375 million to $400 million, including product sales in Latin America and Turkey, royalties in Europe, and royalties in North America.
- Dojolvi revenue is expected to be in the range of $75 million to $80 million.
- Net cash used in operations is expected to be less than $400 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...